Related Experiment Video
Updated: May 2, 2026

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
25.1K
Deep brain stimulation in VPS13C-associated Parkinson's disease: a longitudinal case study
Hiroyuki Sumikura1, Naoki Tani2, Hiroyo Yoshino3
1Department of Neurology, Osaka General Medical Center, 3-1-56 Bandai-higashi, Sumiyoshi-ku, Osaka city 558-8558, Osaka, Japan.
Clinical Parkinsonism & Related Disorders
|May 1, 2026
Summary
VPS13C parkinsonism initially improved with subthalamic nucleus deep brain stimulation (STN-DBS) but rapidly declined. This case highlights the need for genetic testing before STN-DBS in early-onset Parkinson
Area of Science:
- Neuroscience
- Genetics
- Neurological Disorders
Background:
- Subthalamic nucleus deep brain stimulation (STN-DBS) is a treatment for Parkinson's disease.
- VPS13C parkinsonism is a rare genetic form of early-onset Parkinson's disease.
- The long-term efficacy of STN-DBS in genetic Parkinsonism is not well-established.
Keywords:
Autonomic denervationDeep brain stimulationEarly-onset parkinsonismMIBG scintigraphySurgicogenomicsVPS13Cgenetic Parkinson diseaseMore Related Videos
Related Concept Videos
Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K

